by Udai Banerji, Carla M
L van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Victor Moreno,
Iain R Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G E de Vries,
Sylvie Rottey, Jill Geenen, Ferry Eskens, Marta Gil-Martin, Ellen C Mommers,
Norbert P Koper, Philippe Aftimos
The Lancet
Oncology: Articles| volume 20, issue 8, p1124-1135, August 01, 2019
Trastuzumab duocarmazine
shows notable clinical activity in heavily pretreated patients with
HER2-expressing metastatic cancer, including HER2-positive trastuzumab
emtansine-resistant and HER2-low breast cancer, with a manageable safety
profile. Further investigation of trastuzumab duocarmazine for HER2-positive
breast cancer is ongoing and trials for HER2-low breast cancer and other
HER2-expressing cancers are in preparation.
